The US Food and Drug Administration (FDA) understands the value of patient input in the regulatory decision-making process and has worked to enhance meaningful engagement. In recent years, there has been an increased scientific demand for more systematic and quantitative approaches to incorporate patient input throughout the medical product lifecycle, including to inform regulatory benefit-risk assessments. The use of patient preference information (PPI), elicited using established scientific methods, is a promising strategy for accomplishing this.
informing regulatory decision making. Patient input and empowerment are foundational to a learning healthcare system. A learning healthcare system paradigm can also help us better understand and continuously improve the incorporation of the patient perspective in regulatory decision making.
In this article, we highlight the Food and Drug Administration's Center for Biologics Evaluation
and Research experience and current initiatives on advancing the science of patient input in a regulatory setting, in particular, PPI. We provide a use case that explores how the principles and benefits of PPI applied in shared clinical decision making can be realized and leveraged to enhance regulatory evaluation of innovative therapies. To further advance the application of the science of patient input in our regulatory framework, we compiled a list of example resources that support stakeholders in designing and conducting PPI studies. More collaborative research among stakeholders is needed to establish best practice approaches, ensure scientific validity, and continuously learn and improve the systematic incorporation of scientific patient input throughout the regulatory decision-making process.
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| INTRODUCTION
A patient-centered healthcare system that aligns care with individual patient needs and values has the potential to improve the quality of care delivered and health outcomes not only at the patient level but also at the population level. 1, 2 Multiple cultural and political forces have been moving this vision forward. [2] [3] [4] One area that has received significant attention is that of incorporating the patient perspective into all aspects of the medical product development paradigm, including the regulatory framework for review and approval of new products. 5, 6 The US Food and Drug Administration (FDA) understands the value of patient input in the regulatory decision-making process and has regularly sought patients' input. 7 Over time, FDA's approach for engaging patients has been evolving from a more reactive to proactive approach. For example, in the late 1980s, AIDS patients and advocacy groups actively engaged FDA to express their concerns over the lack of treatment options and the slow pace of the approval process. This CBER is one of several FDA centers with efforts focused on more systematically incorporating the patient perspective throughout the medical product development paradigm. Table 1 
| EXPLORING THE USE OF PATIENT PREFERENCES IN CLINICAL AND REGULATORY SETTINGS
The Medical Device Innovation Consortium (MDIC) defines a preference-sensitive decision as "a decision in which there are multiple diagnostic or treatment options, and the decision of which option to pursue depends on the particular preferences of the decision maker". 16 In the clinical setting, the optimal treatment choice for a patient facing a preference-sensitive decision should be based on a patient's values and preferences. Shared decision making, described in the literature as "an approach which seeks to fully inform patients about the risks and benefits of available treatments and engage them as participants in decisions about the treatments," has been suggested as a means for informing treatment decisions at the point of care. 17 One of the aims of CBER's SPI initiative is to understand how some of these same principles could be leveraged to inform the regulatory decisionmaking process.
An example of a preference-sensitive condition from CBER's experience is sickle cell disease (SCD). SCD is a disorder of hemoglobin that leads to unusually rigid red blood cells, prone to obstruction of Using SCD as an example, we explore how PPI can inform the treatment decisions facing SCD patients and their caregivers and how it can inform the benefit-risk assessments facing regulators.
| Clinical setting
The treatment options available to SCD patients and/or their care- (Table 2) .
Different patients may value these outcomes and tolerate these risks differently. Hence, the treatment choice for SCD patients is preference-sensitive and consequently should incorporate their preferences and values.
| Regulatory setting
Patient input can be valuable to regulators at many points throughout the regulatory decision-making process. For example, it can be used to better understand novel treatments that involve difficult trade-off decisions. We use SCD to explore how patient preferences could inform regulatory decision making for a novel, hypothetical therapy, Therapy X.
Therapy X has been shown to cure SCD in preclinical models. Therapy X has less theoretical toxicity than the alternative curative treatment, BMT. However, in other settings, Therapy X has been implicated in causing serious adverse effects, which have been fatal in some cases.
If Therapy X were submitted for regulatory review, regulators would weigh the benefits and risks to patients of using the product, as for any other medical therapy. Regulators will have to decide if the potential benefits of Therapy X outweigh its risks. Historically, regulators have made such decisions based on an evaluation of the available effectiveness and safety data, multidisciplinary expertise, clinical judgment, and other information such as patient input.
Incorporation of patient input can be enhanced through a rigorous, patient preference study that is representative of the patient population. 13, 26 Patient preferences that have been captured using scientifically designed experimental methods allow regulators to understand how preferences differ across patients and how patients make benefit-risk trade-offs that align with their specific health condition and personal values. It is important to note that some SCD patients would opt for a potential cure with Therapy X whereas others will opt for noncurative disease management-both are reasonable decisions. For example, some SCD patients, whose • Hydroxyurea can reduce SCD-related complications; interindividual variability in effectiveness
• Other therapies for symptom management including pain management, blood transfusion
• BMT can be curative; substantial risks include potential for serious adverse effects that are sometimes fatal; limited by availability of a donor Example topics for discussion with an individual SCD patient at the point of care:
Given your current SCD status and the therapy(ies) you are using to manage your disease symptoms…
• Would you be willing to accept the potential, significant risks associated with BMT in exchange for potentially curing your SCD?
• [If Yes] Would you like to proceed with BMT?
Regulatory setting
Exploring patient preferences for an innovative SCD therapy, Therapy X About Therapy X:
• Can be curative; risks include potential for developing serious adverse effects that are sometimes fatal
Note: Detailed, qualitative patient input from patients living with SCD has been collected as part of the PFDD initiative. 25 Example questions that could be asked as part of a rigorous patient preference study in SCD patients:
Given your current SCD status and available therapies for managing your disease…
• Would you be willing to enroll in a clinical trial for Therapy X?
• Would you be willing to accept the potential significant risks of Therapy X in exchange for potential cure of your disease?
• Which treatment attributes of Therapy X are most important to you?
SCD indicates sickle cell disease; BMT, bone marrow transplantation; PFDD, Patient-Focused Drug Development.
symptoms are well controlled using available therapies, may opt to stay with their current therapies, whereas others who are not currently benefiting from available therapies may prefer to accept a higher risk with Therapy X. In the presence of such preference heterogeneity, scientifically collected patient input can enable regulators and other stakeholders to understand how patients make benefit-risk trade-offs.
A patient preference study for Therapy X could be designed to capture qualitative and/or quantitative information about how different patients value the benefits (potential SCD cure) and risks (serious adverse effects that are sometimes fatal) of Therapy X (Table 2) 
| OPPORTUNITIES AND AVAILABLE RESOURCES
PPI can be useful in informing regulatory decision making at various stages of medical product development. Patient perspectives can be elicited during early development to help identify the attributes of a novel medical product that are most important to patients. Further, this information can provide insights into the entire landscape of the disease and may be used to help identify relevant clinical end points.
During the later stages of development, when the benefits, risks, and their magnitude are better understood, patient preference studies can be helpful to assess the benefit-risk trade-offs. In the future, other potential applications of PPI can be explored.
Much of the science behind the design and conduct of patient preference studies is not new; however, the application of this science in the regulatory evaluation of medical products is new. As we work to advance the SPI, there are some limitations that we will need to overcome. It will be important to consider multiple factors, such as a patient's baseline characteristics (e.g., age, gender, cognitive levels, and disease severity), sample sizes, scientifically plausible and mean- Harmonized definition for benefit, risk, and recommended format of benefit-risk assessment of medical product, including potential for incorporating patient perspectives ISPOR conjoint analysis task force reports:
• Checklist for conjoint analysis 27 • Experimental design for DCE 28 • Statistical methods for analysis of DCE 30 Harmonized terms used in translational science and medical product development
Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers 26 Example of a patient preference study for hypothetical therapeutic options in rare diseases, quantifying benefit-risk preferences. The study was conducted in rare disease patients (n=721) and caregivers (n=152). medical product development. Important collaborations already exist, and additional collaboration will be needed. 
| CONCLUSION
The systematic incorporation of the patient perspective in the medical product development paradigm has been evolving, driven in part by social change, legislative initiatives, and by patients themselves. We provided an overview of historical and ongoing efforts to incorporate the patient perspective in a regulatory setting. There has been considerable progress in quantitative methods, both within the agency such as through the PPI Guidance, as well as through public-private partnerships, such as the MDIC framework report. We provided a hypothetical scenario showing how PPI for SCD can be incorporated in clinical and regulatory decision making. SPI is a nascent science; we are ready to learn and advance effective application in a regulatory setting. Work continues to identify best practices and opportunities for improving the methods for eliciting PPI and enhancing its application in our regulatory framework. Stakeholders across the healthcare system will need to continue to collaborate to further improve the SPI and enhance its application in medical product development. Further, a learning healthcare system paradigm can help us better understand and continuously improve the incorporation of patient input in regulatory decision making.
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